Pro-Dex FY2026 net income rises to $13.7M
Pro-Dex (PDEX) reported fiscal 2026 net sales of $77.55M, up 16%, and net income of $13.66M, up 52%. Medical-device sales rose 30%, while repair revenue fell 33%. The largest customer accounted for 78% of sales with a supply agreement through 2028. Operating cash flow was $7.24M, and the company repurchased 79,898 shares.
How this was made
The 30-second read
Why it matters
The earnings beat and cash‑flow turnaround provide a fresh catalyst for the stock, while the high customer concentration remains a risk.
Market read
The filing offers new earnings data for a micro‑cap medical‑device firm, presenting a modest trading opportunity.
What to watch
Acquisition of APM adds aerospace exposure, potentially diversifying revenue streams over time.
Background
Pro‑Dex filed its FY2026 Form 10‑K, reporting a 16% sales increase and a $5.7M gain from equity investments.
Ticker impact
FY2026 net income rose to $13.7M, net sales up 16% and operating cash flow turned positive.
likely upward pressure as investors price higher earnings and cash flow
Earnings beat and cash flow improvement are fresh disclosures; however, 78% of sales depend on one customer, creating downside risk.
Market effects
Medical device sector may see modest uplift from higher earnings, but concentration risk highlights supply‑chain fragility.
Limited to US small‑cap investors; no broader regional effect.
Low global relevance beyond niche medical‑device investors.
Counterpoint
The heavy reliance on a single customer could trigger a sell‑off if the contract is renegotiated or lost.
Key entities
- companyPro‑Dex, Inc.
Medical‑device manufacturer reporting FY2026 results.
